Takeda Pharmaceutical (TKPHF) Other Non-Current Liabilities (2017 - 2026)

Takeda Pharmaceutical's Other Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $3.8 billion for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 8.75% year-over-year to $3.8 billion; the TTM figure through Mar 2026 stood at $3.8 billion (up 8.75% YoY), while the FY2026 annual figure was $4.0 billion, up 13.12% from the prior year.
• Other Non-Current Liabilities was $3.8 billion for Q1 2026 at Takeda Pharmaceutical, up from $3.7 billion in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.6 billion in Q3 2023 to a low of $423.1 million in Q1 2023.
• Historically, Other Non-Current Liabilities has averaged $3.1 billion across 5 years, with a median of $3.5 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Other Non-Current Liabilities decreased 25.36% in 2024, then jumped 539.84% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $3.3 billion in 2022, then decreased by 2.55% to $3.3 billion in 2023, then rose by 13.14% to $3.7 billion in 2024, then rose by 0.67% to $3.7 billion in 2025, then grew by 2.22% to $3.8 billion in 2026.
• The last three Other Non-Current Liabilities figures came in at $3.8 billion (Q1 2026), $3.7 billion (Q4 2025), and $3.7 billion (Q3 2025), per Business Quant data.